commercialisation of hepatitis b vaccine

SciGen and NasVax Execute a Joint Development &
Commercialization Agreement.

10th December 2007: Scigen Limited (ASX:SIE) announces that it has executed a Joint Development & Commercialization Agreement with NasVax Ltd. to jointly develop and commercialize a prophylactic intranasal Hepatitis B vaccine. The product subject of the collaboration is under development, and will combine antigens for immunization against Hepatitis B produced by SciGen with Nasvax unique adjuvant technology, and will be directed towards intranasal delivery. Moreover, SciGen was granted an option, exercisable during the 12 months after the execution of the Agreement, to obtain a onexclusive license to use Nasvax technology to develop an intramuscular prophylactic Hepatitis B vaccine under conditions to be mutually determined in the future.

According to Mr. Saul Mashaal, Chairman & CEO of SciGen Ltd. this Agreement provides new opportunities in respect to the development of a new delivery for the Hepatitis B vaccine, especially in newborn and children, by combining the unique echnologies of both companies that will address the market's demand for improved
efficiency, reduction of the amount of repetitions necessary for vaccination and
intranasal immunization.

The world market for Hepatitis vaccines is presently estimated at about 1.3 Billion U.S.
Dollars.